Continuing the Dialogue in IBS-C Management: Importance of Individualizing Care and Tailoring Treatment.
作者信息
Spiegel Brennan
机构信息
Professor of Medicine and Public Health Director of Health Services Research Director, Master's Degree Program in Health Delivery Science Site Director, Clinical and Translational Science Institute Cedars-Sinai Medical Center Los Angeles, California.
出版信息
Gastroenterol Hepatol (N Y). 2024 Oct;20(10):598-627.
Abstract
摘要
相似文献
1
Continuing the Dialogue in IBS-C Management: Importance of Individualizing Care and Tailoring Treatment.
Gastroenterol Hepatol (N Y). 2024 Oct;20(10):598-627.
2
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire.
Adv Ther. 2018 Jul;35(7):967-980. doi: 10.1007/s12325-018-0733-x. Epub 2018 Jun 26.
3
Phenotyping of subjects for large scale studies on patients with IBS.
Neurogastroenterol Motil. 2016 Aug;28(8):1134-47. doi: 10.1111/nmo.12886. Epub 2016 Jun 19.
4
Irritable bowel syndrome - less irritable, or better treatments?
Curr Opin Gastroenterol. 2024 Jan 1;40(1):27-33. doi: 10.1097/MOG.0000000000000987. Epub 2023 Oct 19.
5
New treatments for IBS.
Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):13-23. doi: 10.1038/nrgastro.2012.207. Epub 2012 Nov 13.
6
Moral foundations theory, political identity, and the depiction of morality in children's movies.
PLoS One. 2021 Mar 26;16(3):e0248928. doi: 10.1371/journal.pone.0248928. eCollection 2021.
7
A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.
Gastroenterol Hepatol (N Y). 2024 Jul;20(7):383-427.
8
The Neutrophil-to-Albumin Ratio (NAR): A Novel Index in Relation to Clinical Symptoms, Quality of Life, and Psychological Status in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
J Inflamm Res. 2024 Jun 10;17:3685-3695. doi: 10.2147/JIR.S458363. eCollection 2024.
9
The burden of illness of irritable bowel syndrome: current challenges and hope for the future.
J Manag Care Pharm. 2004 Jul-Aug;10(4):299-309. doi: 10.18553/jmcp.2004.10.4.299.
10
Association Between Ethnicity and Treatment Preferences in Patients with Irritable Bowel Syndrome.
Rambam Maimonides Med J. 2025 Apr 29;16(2):e0007. doi: 10.5041/RMMJ.10542.
引用本文的文献
1
Raising Expectations in IBS-C Management.
Gastroenterol Hepatol (N Y). 2025 Apr;21(4):218-231.
本文引用的文献
1
Managing IBS-C: Focus on Symptom Control.
Gastroenterol Hepatol (N Y). 2024 Apr;20(4):216-226.
2
Mechanism of Action Considerations in the Management of IBS-C.
Gastroenterol Hepatol (N Y). 2023 Dec;19(12):749-756.
3
Differential Diagnosis of Chronic Diarrhea: An Algorithm to Distinguish Irritable Bowel Syndrome With Diarrhea From Other Organic Gastrointestinal Diseases, With Special Focus on Exocrine Pancreatic Insufficiency.
J Clin Gastroenterol. 2023 Aug 1;57(7):663-670. doi: 10.1097/MCG.0000000000001855.
4
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
Gastroenterology. 2022 Jul;163(1):118-136. doi: 10.1053/j.gastro.2022.04.016.
5
Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
Am J Gastroenterol. 2022 Apr 1;117(4S):S21-S26. doi: 10.14309/ajg.0000000000001709.
6
Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
Am J Gastroenterol. 2022 Apr 1;117(4S):S6-S13. doi: 10.14309/ajg.0000000000001687.
7
Rome Foundation Clinical Diagnostic Criteria for Disorders of Gut-Brain Interaction.
Gastroenterology. 2022 Mar;162(3):675-679. doi: 10.1053/j.gastro.2021.11.019. Epub 2021 Nov 19.
8
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier.
Front Nutr. 2021 Sep 13;8:718356. doi: 10.3389/fnut.2021.718356. eCollection 2021.
9
Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders.
Neurogastroenterol Motil. 2022 Apr;34(4):e14253. doi: 10.1111/nmo.14253. Epub 2021 Sep 14.
10
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.
Aliment Pharmacol Ther. 2021 Jul;54(2):98-108. doi: 10.1111/apt.16437. Epub 2021 Jun 11.
Zotero 插件